Overview
Pontocerebellar hypoplasia type 1 (PCH1), also known as pontocerebellar hypoplasia with spinal muscular atrophy, is a rare and severe neurodegenerative disorder characterized by underdevelopment (hypoplasia) of the pons and cerebellum — structures in the brainstem and hindbrain critical for motor coordination, balance, and many autonomic functions. The condition combines features of cerebellar hypoplasia with progressive degeneration of anterior horn cells in the spinal cord, similar to what is seen in spinal muscular atrophy (SMA). PCH1 is genetically heterogeneous, with several subtypes identified including PCH1A (caused by mutations in the VRK1 gene), PCH1B (caused by mutations in the EXOSC3 gene, the most common form), PCH1C (EXOSC8), and PCH1D (SLC25A46), among others. Clinical features typically present at birth or in early infancy and include severe generalized muscle weakness and hypotonia, respiratory insufficiency, feeding difficulties, absent or markedly reduced deep tendon reflexes, and progressive microcephaly. Affected infants often show little spontaneous movement, and many develop contractures. Neuroimaging reveals a characteristically small cerebellum and pons, with progressive cerebellar atrophy over time. Additional features may include visual impairment, seizures, and intellectual disability, though the severity of neurological involvement is profound in most cases. The prognosis for PCH1 is generally poor, with many affected children dying in infancy or early childhood due to respiratory failure or other complications. There is currently no cure or disease-modifying treatment available. Management is entirely supportive and may include respiratory support (including mechanical ventilation), nutritional support via gastrostomy tube, physical therapy, and seizure management when needed. Genetic counseling is recommended for affected families.
Also known as:
Clinical phenotype terms— hover any for plain English:
Autosomal recessive
Passed on when both parents carry the same gene change; often skips generations
Neonatal
Begins at or shortly after birth (first 4 weeks)
FDA & Trial Timeline
1 eventMedical University of Vienna — NA
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
No FDA-approved treatments are currently listed for Pontocerebellar hypoplasia type 1.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Pontocerebellar hypoplasia type 1 at this time.
New trials open frequently. Follow this disease to get notified.
Rare Disease Specialist
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Pontocerebellar hypoplasia type 1.
Community
No community posts yet. Be the first to share your experience with Pontocerebellar hypoplasia type 1.
Start the conversation →Latest news about Pontocerebellar hypoplasia type 1
Disease timeline:
New trial: Education & Care in RARE: Efficacy of Targeted Psychoeducational Intervention Among Pediatric Rare D
Phase NA trial recruiting. Education & Care in RARE
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Pontocerebellar hypoplasia type 1
What is Pontocerebellar hypoplasia type 1?
Pontocerebellar hypoplasia type 1 (PCH1), also known as pontocerebellar hypoplasia with spinal muscular atrophy, is a rare and severe neurodegenerative disorder characterized by underdevelopment (hypoplasia) of the pons and cerebellum — structures in the brainstem and hindbrain critical for motor coordination, balance, and many autonomic functions. The condition combines features of cerebellar hypoplasia with progressive degeneration of anterior horn cells in the spinal cord, similar to what is seen in spinal muscular atrophy (SMA). PCH1 is genetically heterogeneous, with several subtypes iden
How is Pontocerebellar hypoplasia type 1 inherited?
Pontocerebellar hypoplasia type 1 follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Pontocerebellar hypoplasia type 1 typically begin?
Typical onset of Pontocerebellar hypoplasia type 1 is neonatal. Age of onset can vary across affected individuals.
Which specialists treat Pontocerebellar hypoplasia type 1?
5 specialists and care centers treating Pontocerebellar hypoplasia type 1 are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.